BBlogFlow

Premier Susan Holt takes your health-care questions - CBC

·Oct 2, 2026

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

Skip to Main ContentAccessibility HelpMenuCBC GemCBC ListenSearchQuick LinksNewsSportsRadioMusicListen LiveTVWatchnewsTop StoriesLocalClimateWorldCanadaPoliticsIndigenousBusinessThe NationalHealthEntertainmentScienceCBC News InvestigatesDisability LifeGo PublicAbout CBC NewsBeing Black in CanadaVideoPremier Susan Holt takes your health-care questions | CBC.ca LoadedPremier Susan Holt takes your health-care questionsOctober 2|Duration 11:59October 2NewsDuration 11:59closed captionPremier Susan Holt appeared on Information Morning Fredericton to take New Brunswickers’ questions about health care. Related StoriesHolt Liberals changing how they calculate primary-care accessN. L.'s new health minister says negotiating a federal pharmacare deal is a top 'priority'Audit finds lack of data, cost gaps in Holt’s collaborative care clinicsQ&A | Why the Whitehorse hospital is under strain — and what's being done about itN. L. plans to study expansion of St. Clare's hospital.

This article is an excerpt. To read the full content, visit the original source. CBC

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·